Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer | Zendy

Ahmad Awada | Zendy; Rámón Colomer | Zendy; Kenichi Inoue | Zendy; Igor Bondarenko | Zendy; Rajendra Badwe | Zendy; Georgia Demetriou | Zendy; Soo Chin Lee | Zendy; Ajay Mehta | Zendy; SungBae Kim | Zendy; Thomas Bachelot | Zendy; Chanchal Goswami | Zendy; Suryanarayan V.S. Deo | Zendy; Ron Bose | Zendy; Alvin Wong | Zendy; Feng Xu | Zendy; Bin Yao | Zendy; Richard Bryce | Zendy; Lisa A. Carey | Zendy

Open Access

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

Author(s) -

Ahmad Awada,

Rámón Colomer,

Kenichi Inoue,

Igor Bondarenko,

Rajendra Badwe,

Georgia Demetriou,

Soo Chin Lee,

Ajay Mehta,

SungBae Kim,

Thomas Bachelot,

Chanchal Goswami,

Suryanarayan V.S. Deo,

Ron Bose,

Alvin Wong,

Feng Xu,

Bin Yao,

Richard Bryce,

Lisa A. Carey

Publication year - 2016

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2016.0237

Subject(s) - medicine , trastuzumab , lapatinib , neratinib , metastatic breast cancer , paclitaxel , oncology , breast cancer , population , taxane , cancer , environmental health

Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore